Nifty
:
25571.25
Sensex
:
82814.71
116.90 (0.46%)
316.57 (0.38%)
Nifty
Sensex
:
:
25571.25
82814.71
116.90 (0.46%)
316.57 (0.38%)

Wanbury Ltd.

Pharmaceuticals & Drugs

Rating :
69/99

BSE: 524212 | NSE: WANBURY

NSE BSE
269.97
20-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  260
  •  274.9
  •  258.43
  •  261.14
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  195605
  •  52583306.91
  •  329.7
  •  154.01

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 941.62
  • 14.56
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,102.02
  • N/A
  • 7.65

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.07%
  • 6.60%
  • 41.28%
  • FII
  • DII
  • Others
  • 0.72%
  • 0.00%
  • 8.33%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.54
  • 8.84
  • 6.26

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.62
  • 33.99
  • 24.01

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.82
  • 13.82
  • 22.74

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 143.31
  • 172.79
  • 20.64

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.72
  • 12.84
  • 10.37

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
0.00
161.19
-100.00%
163.18
131.11
24.46%
172.00
139.76
23.07%
133.45
145.50
-8.28%
Expenses
0.00
141.18
-100.00%
138.74
120.13
15.49%
142.37
121.24
17.43%
119.51
124.35
-3.89%
EBITDA
0.00
20.01
-100.00%
24.44
10.97
122.79%
29.63
18.52
59.99%
13.95
21.15
-34.04%
EBIDTM
0.00%
12.41%
14.98%
8.37%
17.23%
13.25%
10.45%
14.53%
Other Income
0.00
1.63
-100.00%
0.35
0.95
-63.16%
1.84
0.57
222.81%
0.84
0.69
21.74%
Interest
0.00
10.15
-100.00%
7.54
7.59
-0.66%
9.04
7.46
21.18%
10.17
8.26
23.12%
Depreciation
0.00
3.32
-100.00%
3.64
3.29
10.64%
3.37
3.28
2.74%
3.32
3.32
0.00%
PBT
0.00
8.17
-100.00%
13.61
1.04
1,208.65%
19.05
33.91
-43.82%
1.29
10.25
-87.41%
Tax
0.00
0.15
-100.00%
0.12
0.00
0
-1.20
0.27
-
0.07
-0.02
-
PAT
0.00
8.02
-100.00%
13.49
1.04
1,197.12%
20.26
33.63
-39.76%
1.22
10.27
-88.12%
PATM
0.00%
4.97%
8.27%
0.79%
11.78%
24.06%
0.91%
7.06%
EPS
0.00
2.45
-100.00%
4.10
0.32
1,181.25%
6.18
10.27
-39.82%
0.37
3.14
-88.22%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
629.82
599.51
577.74
499.65
511.19
392.52
367.45
391.37
371.10
433.81
423.26
Net Sales Growth
12.30%
3.77%
15.63%
-2.26%
30.23%
6.82%
-6.11%
5.46%
-14.46%
2.49%
 
Cost Of Goods Sold
303.55
294.47
303.59
303.44
300.28
221.33
175.74
196.20
174.09
196.97
182.40
Gross Profit
326.27
305.04
274.15
196.20
210.90
171.19
191.72
195.17
197.01
236.83
240.87
GP Margin
51.80%
50.88%
47.45%
39.27%
41.26%
43.61%
52.18%
49.87%
53.09%
54.59%
56.91%
Total Expenditure
541.80
531.83
505.65
476.57
479.45
376.85
389.07
378.00
439.03
415.28
390.89
Power & Fuel Cost
-
24.24
25.17
20.59
18.41
17.13
15.38
14.46
15.26
18.74
18.51
% Of Sales
-
4.04%
4.36%
4.12%
3.60%
4.36%
4.19%
3.69%
4.11%
4.32%
4.37%
Employee Cost
-
104.24
86.92
81.00
74.81
64.15
67.48
75.72
87.10
87.59
85.41
% Of Sales
-
17.39%
15.04%
16.21%
14.63%
16.34%
18.36%
19.35%
23.47%
20.19%
20.18%
Manufacturing Exp.
-
13.76
13.31
11.43
12.66
9.98
13.77
7.98
10.21
15.04
12.34
% Of Sales
-
2.30%
2.30%
2.29%
2.48%
2.54%
3.75%
2.04%
2.75%
3.47%
2.92%
General & Admin Exp.
-
30.60
26.59
22.72
20.58
23.63
28.56
30.47
29.66
34.37
29.80
% Of Sales
-
5.10%
4.60%
4.55%
4.03%
6.02%
7.77%
7.79%
7.99%
7.92%
7.04%
Selling & Distn. Exp.
-
31.25
26.65
21.27
31.31
16.86
19.63
27.41
29.49
42.43
34.19
% Of Sales
-
5.21%
4.61%
4.26%
6.12%
4.30%
5.34%
7.00%
7.95%
9.78%
8.08%
Miscellaneous Exp.
-
33.27
23.40
16.12
21.40
23.78
68.51
25.77
93.22
20.14
34.19
% Of Sales
-
5.55%
4.05%
3.23%
4.19%
6.06%
18.64%
6.58%
25.12%
4.64%
6.68%
EBITDA
88.03
67.68
72.09
23.08
31.74
15.67
-21.62
13.37
-67.93
18.53
32.37
EBITDA Margin
13.98%
11.29%
12.48%
4.62%
6.21%
3.99%
-5.88%
3.42%
-18.31%
4.27%
7.65%
Other Income
4.66
12.12
0.90
1.01
5.09
4.75
46.20
11.50
76.70
89.69
1.40
Interest
36.90
36.95
29.18
21.39
20.61
23.07
32.87
39.88
30.86
35.51
31.87
Depreciation
13.65
13.31
13.03
12.38
11.45
9.75
9.68
9.97
10.30
10.32
9.05
PBT
42.12
29.55
30.78
-9.69
4.76
-12.41
-17.97
-24.98
-32.39
62.40
-7.15
Tax
-0.86
-0.98
0.38
0.11
-0.35
0.20
0.21
-0.14
-0.38
0.38
0.00
Tax Rate
-2.04%
-3.32%
0.67%
-1.07%
-0.43%
-1.61%
0.32%
0.56%
1.17%
0.61%
0.00%
PAT
42.99
30.53
55.96
-10.40
81.47
-12.61
64.46
-24.85
-32.01
62.01
-7.15
PAT before Minority Interest
42.99
30.53
55.96
-10.40
81.47
-12.61
64.46
-24.85
-32.01
62.01
-7.15
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
6.83%
5.09%
9.69%
-2.08%
15.94%
-3.21%
17.54%
-6.35%
-8.63%
14.29%
-1.69%
PAT Growth
-17.80%
-45.44%
-
-
-
-
-
-
-
-
 
EPS
12.32
8.75
16.03
-2.98
23.34
-3.61
18.47
-7.12
-9.17
17.77
-2.05

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
59.27
27.94
-32.82
-23.42
-156.24
-143.45
-209.28
-184.68
-153.28
-188.77
Share Capital
32.77
32.75
32.71
32.67
25.02
25.00
23.72
23.72
23.22
19.97
Total Reserves
18.64
-11.64
-67.15
-57.01
-181.60
-168.66
-233.23
-208.66
-176.50
-220.96
Non-Current Liabilities
173.00
98.98
10.81
10.56
84.43
107.74
130.36
105.79
159.92
251.37
Secured Loans
160.29
82.00
0.00
0.00
71.99
99.54
123.03
99.01
153.73
230.92
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
17.45
15.51
13.93
12.07
13.75
11.56
10.69
10.14
9.55
8.76
Current Liabilities
174.61
210.70
320.03
359.77
355.35
311.04
361.60
348.25
401.91
298.61
Trade Payables
138.46
162.75
148.71
179.56
133.77
121.87
112.24
83.13
140.11
86.11
Other Current Liabilities
29.43
31.61
153.93
162.35
200.56
160.75
160.69
178.59
194.50
118.92
Short Term Borrowings
4.16
14.27
13.19
13.21
16.42
24.92
85.21
82.67
63.19
90.60
Short Term Provisions
2.56
2.07
4.19
4.66
4.60
3.50
3.47
3.85
4.12
2.97
Total Liabilities
406.88
337.62
298.02
346.91
283.54
275.33
282.68
269.36
408.55
387.87
Net Block
200.60
166.82
167.11
167.11
167.38
163.90
172.36
178.33
186.34
180.27
Gross Block
292.82
248.41
239.29
226.95
215.98
203.10
202.03
198.61
196.65
325.72
Accumulated Depreciation
92.21
81.58
72.18
59.84
48.59
39.20
29.66
20.28
10.32
145.46
Non Current Assets
213.44
179.01
174.24
173.71
182.28
181.69
184.53
191.66
216.83
223.94
Capital Work in Progress
5.38
3.01
1.61
2.35
11.01
13.89
8.97
10.05
9.58
14.42
Non Current Investment
0.02
0.03
0.01
0.01
0.01
0.01
0.02
0.02
0.03
0.01
Long Term Loans & Adv.
5.90
5.72
5.03
3.80
3.40
3.80
3.11
2.84
20.46
28.98
Other Non Current Assets
1.53
3.44
0.49
0.44
0.46
0.10
0.07
0.41
0.43
0.26
Current Assets
193.44
158.61
121.81
171.24
97.53
93.64
98.15
77.70
191.73
163.93
Current Investments
0.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
37.68
36.02
21.99
49.73
24.85
12.26
19.33
13.07
34.23
34.61
Sundry Debtors
114.16
88.76
68.98
62.80
34.47
50.79
44.41
29.46
84.66
74.94
Cash & Bank
12.83
5.90
3.93
25.31
11.70
16.70
5.25
6.21
9.37
7.22
Other Current Assets
28.65
6.65
3.97
5.40
26.51
13.89
29.16
28.96
63.47
47.15
Short Term Loans & Adv.
24.86
21.27
22.94
28.00
3.42
4.47
2.69
6.27
37.16
29.41
Net Current Assets
18.83
-52.09
-198.22
-188.53
-257.82
-217.41
-263.44
-270.55
-210.19
-134.68
Total Assets
406.88
337.62
296.05
344.95
279.81
275.33
282.68
269.36
408.56
387.87

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
26.10
4.70
19.80
40.52
16.68
44.13
29.73
32.49
43.39
43.05
PBT
29.55
56.34
-10.29
81.13
-12.41
64.67
-24.98
-32.39
62.40
-7.15
Adjustment
47.98
16.05
37.01
-43.68
33.22
-41.41
42.90
39.71
-37.29
47.85
Changes in Working Capital
-51.06
-67.51
-6.75
3.24
-3.00
20.90
11.88
26.05
18.33
2.36
Cash after chg. in Working capital
26.47
4.88
19.97
40.69
17.81
44.16
29.80
33.37
43.43
43.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.37
-0.18
-0.17
-0.16
-1.13
-0.03
-0.06
-0.89
-0.04
-0.01
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-51.17
-16.63
-8.84
0.59
8.04
63.66
-3.07
-1.39
-13.06
-19.63
Net Fixed Assets
-46.78
-10.52
-11.60
-2.31
-10.00
-5.99
-2.34
-2.43
133.91
-15.98
Net Investments
-0.12
-0.02
0.00
0.00
0.00
0.01
0.00
0.01
-0.02
0.00
Others
-4.27
-6.09
2.76
2.90
18.04
69.64
-0.73
1.03
-146.95
-3.65
Cash from Financing Activity
25.73
13.87
-31.99
-28.58
-17.39
-107.87
-26.78
-33.26
-26.93
-28.07
Net Cash Inflow / Outflow
0.66
1.94
-21.03
12.52
7.34
-0.08
-0.13
-2.16
3.39
-4.65
Opening Cash & Equivalents
3.40
1.46
22.53
10.00
2.66
2.74
2.87
5.03
1.63
6.28
Closing Cash & Equivalent
4.06
3.40
1.49
22.53
10.00
2.66
2.74
2.87
5.03
1.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
15.69
6.44
-10.57
-7.55
-62.60
-57.48
-88.32
-77.97
-66.01
-112.21
ROA
8.20%
17.61%
-3.22%
25.85%
-4.51%
23.10%
-9.00%
-9.44%
15.57%
-1.82%
ROE
84.21%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
ROCE
35.97%
101.56%
29.82%
428.78%
87.61%
444.45%
50.26%
-2.00%
70.48%
15.27%
Fixed Asset Turnover
2.23
2.39
2.18
2.32
1.88
1.83
2.08
2.00
1.70
1.37
Receivable days
61.39
49.39
47.23
34.50
39.45
46.85
32.42
52.61
65.66
72.98
Inventory Days
22.30
18.16
25.70
26.45
17.17
15.54
14.22
21.80
28.32
28.77
Payable days
186.68
187.23
197.43
190.42
210.79
243.11
106.12
125.89
110.93
100.14
Cash Conversion Cycle
-103.00
-119.68
-124.50
-129.47
-154.17
-180.72
-59.49
-51.47
-16.96
1.60
Total Debt/Equity
3.37
5.18
-1.86
-2.72
-1.02
-1.14
-1.11
-1.19
-1.76
-1.67
Interest Cover
1.80
2.93
0.52
4.94
0.46
2.97
0.37
-0.05
2.76
0.78

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Wanbury starts commercial production of high-potent anaesthetic API at Tanuku facility
    28th Jan 2026, 12:50 PM

    The new API is expected to generate incremental revenues of around Rs 18 crore in Q4 FY 2025-26

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.